目的 探討氯替潑諾聯(lián)合聚乙烯醇滴眼液治療干眼癥的臨床療效。方法 選取2016年8月-2018年8月滄州眼科醫(yī)院收治的干眼癥患者140例，隨機分為對照組（70例）和治療組（70例）。對照組給予聚乙烯醇滴眼液，1滴/次，4次/d。治療組在對照組基礎(chǔ)上給予氯替潑諾混懸滴眼液，1滴/次，4次/d。兩組患者均連續(xù)治療8周。觀察兩組患者臨床療效，同時比較治療前后兩組患者干眼癥狀評分、淚膜破裂時間（BUT）、淚液分泌長度和角膜熒光素染色（FL）評分評分，及淚液中白細(xì)胞介素-33（IL-33）、胸腺基質(zhì)淋巴細(xì)胞生成素（TSLP）水平。結(jié)果 治療后，對照組臨床有效率為89.29%，顯著低于治療組的97.14%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者干眼癥狀評分均明顯低于治療前（P<0.05），且治療組患者干眼癥狀評分顯著低于對照組（P<0.05）。治療后，兩組患者BUT、淚液分泌長度均明顯長于治療前（P<0.05），而FL評分顯著低于治療前（P<0.05），且治療組患者BUT、淚液分泌長度均顯著長于對照組（P<0.05），F(xiàn)L評分明顯低于對照組（P<0.05）。治療后，兩組患者淚液中IL-33、TSLP水平均明顯低于治療前（P<0.05），且治療組患者淚液中IL-33、TSLP水平均顯著低于對照組（P<0.05）。結(jié)論 氯替潑諾聯(lián)合聚乙烯醇滴眼液治療干眼癥臨床效果好，能有效促進患者淚膜穩(wěn)定性，減輕炎癥反應(yīng)。

Objective To investigate the clinical effect of loteprednol etabonate combined with Polyvinyl Alcohol Eye Drops in treatment of xerophthalmia. Methods Patients (140 cases) with xerophthalmia in Cangzhou Eye Hospital from August 2016 to August 2018 were randomly divided into control (70 cases) and treatment (70 cases) groups. Patients in the control group were administered with Polyvinyl Alcohol Eye Drops, 1 drop/time, four times daily. Patients in the treatment group were administered with Loteprednol Etabonate Ophthalmic Suspension on the basis of the control group, 1 drop/time, four times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the dry eye symptom scores, BUT, lacrimal secretion length and FL scores, IL-33 and TSLP levels of tear in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 89.29%, which was significantly lower than 97.14% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the dry eye symptom scores in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than that in the control group (P<0.05). After treatment, the BUT, lacrimal secretion length in two groups were significantly increased (P<0.05) and were significantly longer that in the control group, but the FL scores were significantly decreased (P<0.05), and which in the treatment group were significantly lower than that in the control group (P<0.05). After treatment, the IL-33 and TSLP levels of tear in two groups were significantly decreased (P<0.05), and the IL-33 and TSLP levels in the treatment group were significantly lower than that in the control group (P<0.05). Conclusion Loteprednol etabonate combined with Polyvinyl Alcohol Eye Drops is effective in treatment of xerophthalmia, which can effectively promote tear film stability and reduce inflammation.

R988.1

滄州市科技計劃項目（162302058）